Oxular Limited is an Oxford-based retinal therapeutics development company focused on combining proprietary drug delivery technology and drug formulations to treat sight-threatening diseases.
The company was founded in early 2016 with an Innovations-led £15.5 million funding round, which included the participation of NeoMed and V-Bio Ventures, Consort Medical, and Hovione Scientia. Consort Medical and Hovione Scientia each have development partnerships with Oxular.
Oxular’s delivery technology enables routine injection to deliver drugs and therapeutics to specific tissues in the back of eye, resulting in improved therapeutic benefits and safety. The company’s drug formulations are optimised to suit the unique ocular environments where they are delivered, resulting in better pharmacokinetics (drug movement) and pharmacodynamics (therapeutic effect) as well as extended treatment durations.
Oxular’s lead programme is a drug/device combination product that is prepared in a preloaded, single-use, injection instrument and is being developed to treat adults with a number of eye conditions including diabetic macular oedema (DME) and retinal vein occlusion (RVO).